Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Kalafateli M
  • Forlano R
  • Barnes E
  • Martinez-Gili L
  • Lacey M
  • Sigon G
  • Mullish BH
  • Mallet V
  • Parlati L
  • Richardson P
  • Forde N
  • Serviddio G
  • Villani R
  • Lens S
  • Buti M
  • Vargas E
  • Viganò M
  • Loglio A
  • Lampertico P
  • D'ambrosio R
  • Monico S
  • Maffi G
  • Lombardi R
  • Fracanzani AL
  • De Luca C
  • Ingiliz P
  • Mangia A
  • Leserre F
  • Napolitano AM
  • Piazzolla V
  • Russo FP
  • Raimondo G
  • Cacciola I
  • Saitta C
  • Lemoine M
  • Papatheodoridis G
  • Papatheodoridi M
  • Samonakis DN
  • O'Donnell D
  • O'Donoghue J
  • Abeles RD
  • Pugliese N
  • Aghemo A
  • Brown A
  • Thursz MR
  • Manousou P

Grupos

Abstract

BACKGROUND & AIMS: Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) commonly co-exist, with conflicting data in prevalence and disease severity. We aimed to investigate these discrepancies. METHODS: This multicenter study included consecutive patients with CHB from 19 European centers. A survey on standard of care for MASLD screening in CHB was circulated. RESULTS: A total of 1709 patients with CHB were included; median age, 53 years (interquartile range [IQR], 42-64); males, 60.7%; body mass index (BMI), 25.6 kg/m(2) (IQR, 14-63 kg/m(2)); and 57.3% White. MASLD prevalence (1510 consecutive patients) was 42.3%. BMI (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.19-1.36), ferritin (OR, 1.00; 95% CI, 1.00-1.00) and type 2 diabetes (OR, 2.60; 95% CI, 1.12-6.02) were independently associated with MASLD. The prevalence of advanced fibrosis was 18% (255/1420) in the whole cohort, 25.4% (162/639) among patients with CHB with MASLD, and 13.7% in those without MASLD. Independent predictors of advanced fibrosis were MASLD (OR, 2.76; 95% CI, 1.50-5.05), BMI (OR, 1.08; 95% CI, 1.02-1.15), alanine transaminase (OR, 1.01; 95% CI, 1.00-1.03), lower platelets (OR, 0.99; 95% CI, 0.98-0.99), insulin treatment (OR, 13.88; 95% CI, 2.95-65.28), and long-term antivirals (OR, 4.86; 95% CI, 2.40-9.85). During follow-up (48 months), only patients without MASLD showed significant liver stiffness measurement improvement over time (P < .001). Among patients with MASLD, Fibrosis-4 and liver stiffness measurement performed moderately at predicting advanced fibrosis (area under the receiver operating characteristic curve = 0.71 vs 0.70; P = .38) against histology. As standard of care, 68.4% of centers screened all patients with CHB for MASLD; 52.6% followed the same treatment indication in those with CHB and MASLD vs CHB only. CONCLUSION: In this large European cohort, MASLD and fibrosis were highly prevalent among patients with CHB, whereas MASLD aggravated liver fibrosis. Though screening strategies remain inconsistent, ferritin levels, increased BMI, and type 2 diabetes may inform on the presence of MASLD. Biomarkers showed modest performance in predicting fibrosis.

Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1542-3565, 1542-7714

Clinical Gastroenterology and Hepatology  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
701-7128
PubMed:
40609817
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,691 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 11

Citas Recibidas en Scopus: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Chronic Hepatitis B; Liver Fibrosis; Metabolic Dysfunction-associated Steatotic Liver Disease; Noninvasive Markers

Compartir